KR20250119664A - 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정 - Google Patents

4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정

Info

Publication number
KR20250119664A
KR20250119664A KR1020257025628A KR20257025628A KR20250119664A KR 20250119664 A KR20250119664 A KR 20250119664A KR 1020257025628 A KR1020257025628 A KR 1020257025628A KR 20257025628 A KR20257025628 A KR 20257025628A KR 20250119664 A KR20250119664 A KR 20250119664A
Authority
KR
South Korea
Prior art keywords
compound
salt
formula
chemical formula
organic phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257025628A
Other languages
English (en)
Korean (ko)
Inventor
폴 앨런 베델
라이 춘 찬
케이티 그레이스 쿠퍼
로버트 존 콕스
마이클 데이비드 골든
숀 앨런 휴즈
루신다 빅토리아 잭슨
커스티 제인 밀라드
앤드류 존 필립스
알렉산더 제임스 텔포드
제리 에바츠
마이클 조셉 로울러
레미 이. 제이. 엔. 리진스
피터 요하네스 세르바스 사비오 반 에이크
마틸다 마리아 헨리카 베르스타펜
프랭크 엘. 엠. 보스
에릭 유리엔 제이프
추 정잉
앙앙 왕
루스탐 페르디난드 개리
데이비드 앨런 쇼트
Original Assignee
아세르타 파마. 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아세르타 파마. 비.브이. filed Critical 아세르타 파마. 비.브이.
Publication of KR20250119664A publication Critical patent/KR20250119664A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
KR1020257025628A 2018-08-29 2019-08-28 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정 Pending KR20250119664A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862724228P 2018-08-29 2018-08-29
US62/724,228 2018-08-29
PCT/EP2019/072991 WO2020043787A1 (en) 2018-08-29 2019-08-28 Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
KR1020217008606A KR102842131B1 (ko) 2018-08-29 2019-08-28 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의 제조 공정

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008606A Division KR102842131B1 (ko) 2018-08-29 2019-08-28 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의 제조 공정

Publications (1)

Publication Number Publication Date
KR20250119664A true KR20250119664A (ko) 2025-08-07

Family

ID=67928802

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257025628A Pending KR20250119664A (ko) 2018-08-29 2019-08-28 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
KR1020217008606A Active KR102842131B1 (ko) 2018-08-29 2019-08-28 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의 제조 공정

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217008606A Active KR102842131B1 (ko) 2018-08-29 2019-08-28 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의 제조 공정

Country Status (16)

Country Link
US (3) US12024520B2 (cg-RX-API-DMAC10.html)
EP (1) EP3844149A1 (cg-RX-API-DMAC10.html)
JP (3) JP7439095B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250119664A (cg-RX-API-DMAC10.html)
CN (2) CN112638878B (cg-RX-API-DMAC10.html)
AU (4) AU2019332882B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021003480A2 (cg-RX-API-DMAC10.html)
CA (1) CA3109734A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021003676A2 (cg-RX-API-DMAC10.html)
EA (1) EA202190557A1 (cg-RX-API-DMAC10.html)
IL (3) IL281025B2 (cg-RX-API-DMAC10.html)
MA (1) MA53485A (cg-RX-API-DMAC10.html)
MX (2) MX2021002246A (cg-RX-API-DMAC10.html)
MY (1) MY206899A (cg-RX-API-DMAC10.html)
WO (1) WO2020043787A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA202306381B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
EP3947386A1 (en) * 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
DK4054582T3 (da) 2019-11-04 2025-12-01 Astrazeneca Ab Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter
CR20230018A (es) 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
EP2139487B1 (en) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
CN103889987B (zh) * 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
WO2017077507A1 (en) * 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
CN107056786B (zh) 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
ES2856248T3 (es) 2016-12-21 2021-09-27 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina quinasa de Bruton
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
CN107522701B (zh) 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
US11161851B2 (en) 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
KR20250119664A (ko) * 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-{8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일}N-(피리딘-2-일)-벤즈아미드의제조 공정
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法

Also Published As

Publication number Publication date
CA3109734A1 (en) 2020-03-05
MX2023011692A (es) 2023-10-19
US20240317766A1 (en) 2024-09-26
JP2026021364A (ja) 2026-02-10
KR20210053304A (ko) 2021-05-11
AU2023204660A1 (en) 2023-08-03
IL322382A (en) 2025-09-01
AU2023204660B2 (en) 2024-01-25
WO2020043787A1 (en) 2020-03-05
IL281025B1 (en) 2024-08-01
JP2024037935A (ja) 2024-03-19
US12448387B2 (en) 2025-10-21
AU2022200828B2 (en) 2023-05-25
KR102842131B1 (ko) 2025-08-04
CN112638878A (zh) 2021-04-09
JP2021535220A (ja) 2021-12-16
CN112638878B (zh) 2025-07-22
IL281025A (en) 2021-04-29
JP7829541B2 (ja) 2026-03-13
AU2024202290A1 (en) 2024-05-02
US12024520B2 (en) 2024-07-02
MX2021002246A (es) 2021-05-27
IL312413A (en) 2024-06-01
CN120904205A (zh) 2025-11-07
US20260109701A1 (en) 2026-04-23
MA53485A (fr) 2021-12-08
IL312413B1 (en) 2025-09-01
ZA202306381B (en) 2024-11-27
ZA202409391B (en) 2025-04-30
EA202190557A1 (ru) 2021-07-13
CO2021003676A2 (es) 2021-04-08
AU2022200828A1 (en) 2022-03-03
EP3844149A1 (en) 2021-07-07
JP7439095B2 (ja) 2024-02-27
BR112021003480A2 (pt) 2021-05-18
AU2019332882A1 (en) 2021-04-22
AU2019332882B2 (en) 2022-01-27
IL312413B2 (en) 2026-01-01
MY206899A (en) 2025-01-13
US20220127270A1 (en) 2022-04-28
IL281025B2 (en) 2024-12-01

Similar Documents

Publication Publication Date Title
JP7829541B2 (ja) 4-{8-アミノ-3-[(2S)-1-(ブタ-2-イノイル)-ピロリジン-2-イル]イミダゾ[1,5-a]-ピラジン-1-イル}N-(ピリジン-2-イル)-ベンズアミドの調製のためのプロセス
JP6870082B2 (ja) 二メシル酸パルボシクリブの固体形態
EP2712865A1 (en) Improved process for the preparation of ambrisentan
RS60303B1 (sr) Postupak za pripremu rastopa silicijumdioksida
AU2016214802B2 (en) Diaza-benzofluoranthrene compounds
AU2014359409A1 (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
EA049170B1 (ru) СПОСОБ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-2-ПИРРОЛИДИНИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(2-ПИРИДИНИЛ)БЕНЗАМИДА
HK40041702B (en) Processes for the preparation of acalabrutinib
EA043329B1 (ru) СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
HK40041702A (en) Processes for the preparation of acalabrutinib
IL312472A (en) Evaluation system, evaluation method and evaluation software
US20210188823A1 (en) Method for Producing Diarylpyridine Derivatives
WO2025064325A1 (en) Gpr35 modulators
WO2024059220A2 (en) 6,5 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
HK40035144B (en) Preparation process of two compounds
JP2004075616A (ja) 4−ハロゲノ−2−(4−フルオロフェニルアミノ)−5,6−ジメチルピリミジンの製造方法

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)